Anna Caliò, Antonella Barreca, Stefano Marletta, Maria Italia Sara Achenza, Marianna Alessi, Roberta Angelico, Luca Apicella, Davide Argiolas, Nicola Bossini, Rosa Carrano, Concetta Carriero, Giuseppe Castellano, Giorgia Comai, Caterina Di Bella, Francesco D'Ignoto, Agnese Gallico, Fiorella Gastaldon, Guido Merlotti, Vera Paloschi, Alessandra Panarese, Angelica Parodi, Francesco Perna, Daniela Picciotto, Anna Regalia, Michele Rossini, Enrico Russo, Maria Paola Salerno, Luca Toti, Patrizia Tulissi, Gisella Vischini, Gianluigi Zaza, Albino Eccher
{"title":"肾学组织学,从植入前到移植后肾活检。重生(肾移植治疗的肾活检)的经验教训。","authors":"Anna Caliò, Antonella Barreca, Stefano Marletta, Maria Italia Sara Achenza, Marianna Alessi, Roberta Angelico, Luca Apicella, Davide Argiolas, Nicola Bossini, Rosa Carrano, Concetta Carriero, Giuseppe Castellano, Giorgia Comai, Caterina Di Bella, Francesco D'Ignoto, Agnese Gallico, Fiorella Gastaldon, Guido Merlotti, Vera Paloschi, Alessandra Panarese, Angelica Parodi, Francesco Perna, Daniela Picciotto, Anna Regalia, Michele Rossini, Enrico Russo, Maria Paola Salerno, Luca Toti, Patrizia Tulissi, Gisella Vischini, Gianluigi Zaza, Albino Eccher","doi":"10.32074/1591-951X-858","DOIUrl":null,"url":null,"abstract":"<p><p>A meeting entitled Renal BIopsy for Kidney Transplantation Therapy (ReBIrth) took place on May 31<sup>st</sup>, 2022 in Bologna, Italy. The meeting drew together nephrologists, surgeons, and pathologists and recognized as experts in the field of kidney transplantation in Italy. In this paper, we present our experience working with kidney transplants in the current era of immunosuppression therapy. The primary aim is to report the histopathological characteristics of failed kidney allografts after a consensus of experts reviewed the cases on a wholeslide imaging digital platform. Regardless of the cases discussed, digital pathology was reliable in identifying all the morphological and immunohistochemical features required to improve the correct use of immunosuppressive therapy to prevent graft failure and optimize patient management.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 4","pages":"199-204"},"PeriodicalIF":4.4000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688244/pdf/","citationCount":"0","resultStr":"{\"title\":\"Histology for nephrology, from pre-implantation to post-transplant kidney biopsy. Lesson learned from ReBIrth (Renal BIopsy for Kidney Transplantation Therapy).\",\"authors\":\"Anna Caliò, Antonella Barreca, Stefano Marletta, Maria Italia Sara Achenza, Marianna Alessi, Roberta Angelico, Luca Apicella, Davide Argiolas, Nicola Bossini, Rosa Carrano, Concetta Carriero, Giuseppe Castellano, Giorgia Comai, Caterina Di Bella, Francesco D'Ignoto, Agnese Gallico, Fiorella Gastaldon, Guido Merlotti, Vera Paloschi, Alessandra Panarese, Angelica Parodi, Francesco Perna, Daniela Picciotto, Anna Regalia, Michele Rossini, Enrico Russo, Maria Paola Salerno, Luca Toti, Patrizia Tulissi, Gisella Vischini, Gianluigi Zaza, Albino Eccher\",\"doi\":\"10.32074/1591-951X-858\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A meeting entitled Renal BIopsy for Kidney Transplantation Therapy (ReBIrth) took place on May 31<sup>st</sup>, 2022 in Bologna, Italy. The meeting drew together nephrologists, surgeons, and pathologists and recognized as experts in the field of kidney transplantation in Italy. In this paper, we present our experience working with kidney transplants in the current era of immunosuppression therapy. The primary aim is to report the histopathological characteristics of failed kidney allografts after a consensus of experts reviewed the cases on a wholeslide imaging digital platform. Regardless of the cases discussed, digital pathology was reliable in identifying all the morphological and immunohistochemical features required to improve the correct use of immunosuppressive therapy to prevent graft failure and optimize patient management.</p>\",\"PeriodicalId\":45893,\"journal\":{\"name\":\"PATHOLOGICA\",\"volume\":\"115 4\",\"pages\":\"199-204\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688244/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PATHOLOGICA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32074/1591-951X-858\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/6/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PATHOLOGICA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32074/1591-951X-858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
Histology for nephrology, from pre-implantation to post-transplant kidney biopsy. Lesson learned from ReBIrth (Renal BIopsy for Kidney Transplantation Therapy).
A meeting entitled Renal BIopsy for Kidney Transplantation Therapy (ReBIrth) took place on May 31st, 2022 in Bologna, Italy. The meeting drew together nephrologists, surgeons, and pathologists and recognized as experts in the field of kidney transplantation in Italy. In this paper, we present our experience working with kidney transplants in the current era of immunosuppression therapy. The primary aim is to report the histopathological characteristics of failed kidney allografts after a consensus of experts reviewed the cases on a wholeslide imaging digital platform. Regardless of the cases discussed, digital pathology was reliable in identifying all the morphological and immunohistochemical features required to improve the correct use of immunosuppressive therapy to prevent graft failure and optimize patient management.